Tyra Biosciences Inc
TYRAHealthcare|Biotechnology|USA
$32.75
-0.26 (-0.79%)
Tangible Book
$6.52
Earnings Power
$6.02
Clinical Trials (8)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07265947 Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma | Low Grade Upper Tract Urothelial Carcinoma | P2 | Recruiting | 230 | RCT, Open-label | Dabogratinib (TYRA-300) 60mg, Dabogratinib (TYRA-300) 80mg, Dabogratinib (TYRA-300) TBD |
| NCT06842355 A Study of TYRA-300 in Children With Achondroplasia: BEACH301 | Achondroplasia | P2 | Recruiting | 92 | Open-label | TYRA-300 0.125 mg/kg, TYRA-300 0.25 mg/kg, TYRA-300 0.375 mg/kg, TYRA-300 0.50 mg/kg |
| NCT05544552 Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations | Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma | P1P2 | Active | 310 | Open-label | TYRA-300 |
| NCT06995677 Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer | Low-grade NMIBC, FGFR Gene Amplification | P2 | Recruiting | 90 | RCT, Open-label | TYRA-300 60mg, TYRA-300 50mg, TYRA-300 Dose TBD |
| NCT06915753 Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations | Metastatic Hepatocellular Carcinoma, Solid Tumors | P1 | Recruiting | 100 | Open-label | TYRA-430 |
| NCT06160752 Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations | Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma | P1 | Recruiting | 40 | Open-label | Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles, Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles |
| NCT06006702 A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult Participants | Healthy | P1 | Active | 60 | RCT, Open-label | TYRA-300-B01 |
| NCT04941950 A Digital Intervention to Prevent the Initiation of Opioid Misuse in Adolescents in School-based Health Centers | Opioid Misuse | N/A | Completed | 533 | RCT, Single-blind | — |